Meghan Mooradian

21PUBLICATIONS
139CO-AUTHORS
Predictive and prognostic markersMolecular targetsNatural language processingCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (21)

|Feb 03, 2026
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.

George Ansstas, Karam Khaddour, Sumedha Sudhaman

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Sep 03, 2024
Enhancing Precision in Detecting Severe Immune-Related Adverse Events: Comparative Analysis of Large Language Models and International Classification of Disease Codes in Patient Records.

Virginia H Sun, Julius C Heemelaar, Ibrahim Hadzic

|Aug 27, 2024
Cryoablation and post-progression immune checkpoint inhibition in metastatic melanoma: a phase II trial.

Meghan J Mooradian, Florian J Fintelmann, Thomas J LaSalle

|Jul 27, 2024
Immune-related adverse events requiring hospitalization in patients with lung cancer: implications and insights.

Ayo Falade, Leyre Zubiri, Chia-Yun Wu

|Apr 10, 2024
Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy.

Steven T Chen, Yevgeniy R Semenov, Allireza Alloo

Pageof 4

Frequent Collaborators

11 joint publications

Ryan Sullivan

6 joint publications

Leyre Zubiri

5 joint publications

Michael Dougan

4 joint publications

Kerry L Reynolds